Latest Earnings Results: Q2 '26
Estimated EPS
-$1.22
Reported EPS
-$0.90
Surprise
+26.09%
Estimated Rev
$183.08M
Reported Rev
$214M
Surprise
+16.89%
$RARE Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.90 up 23.08% YoY • Reported revenue of $214M up 28.53% YoY • Ultragenyx Pharmaceutical Inc. reaffirms its 2026 full-year total revenue guidance of $730 million to $760 million, excluding potential new product launches, while remaining on track toward profitability in 2027.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.93 | -- | -- | N/A |
Q2 '26 | -$1.22 | -$0.90 | 26.09% | BEAT |
Q1 '26 | -$1.50 | -$1.84 | -22.93% | MISSED |
Q4 '25 | -$1.09 | -$1.29 | -18.07% | MISSED |
Q3 '25 | -$1.23 | -$1.81 | -46.69% | MISSED |